Pathwork Diagnostics Tissue of Origin Test Clinical Utility Study Presented at American Society of Clinical Oncology GI Symposium

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that results from a decision impact study of its Tissue of Origin Test were presented this weekend at the ASCO 2011 Gastrointestinal Cancers Symposium in San Francisco. In the study of 111 cases derived from more than 65 academic and community practices, after receiving the Tissue of Origin Test results, the determination of the primary diagnosis site and treatment management was changed in more than half of patients.